LENZ Therapeutics

LENZ Therapeutics welcomes Kenny Kolbeck, MBA as Senior Manager, Supply Chain Planning & Logistics. Kenny comes to us with a wealth of experience, having spent the last three years at Glaukos managing their ophthalmic supply chain.  He brings a strong background in cold chain logistics for both ocean and air, as well as demand planning, making him a key asset as we drive towards commercial readiness and product launch support.   Kenny’s previous roles at Merck and Kuehne & Nagel further underscore his extensive expertise, which will be critical in supporting our CMC/Supply Chain function. Join us in welcoming Kenny to the team!

Neena James, OD is thoughtful about her patients' care. She believes that presbyopes deserve the right to have options. “Eye care is all about individualized care, and not just from person to person. Some patients are looking for different solutions from day to day. They might want one vision-correcting option for working on the computer and another for playing golf. When it comes to managing presbyopia, adaptability isn’t just an option—it’s the expectation.” Visit www.EyeAmSelective.com to learn more about future presbyopia solutions. #presbyopia #EyeAmSelective   

CORXEL Pharmaceuticals and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 - Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment, and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). The difference in efficacy was statistically significant in the LNZ100 treatment group compared to the vehicle group (p<0.0001)   - Rapid onset and long duration shown with 69% of participants achieving three-lines or greater improvement at 30 minutes and 30% at 10 hours   - 91% of participants indicated they noticed an improvement in their near vision   - LNZ100 could potentially be the best-in-class non-invasive treatment for presbyopia Read full press release here: https://lnkd.in/ezf8yi62

Erick Henderson, OD, FAAO is confident an approach that targets the iris sphincter will be the future for presbyopia. Are you confident about a future solution for presbyopia? "As a newer optometrist, I’m excited about offering a new solution to my presbyopia patients. An approach that selectively targets the iris sphincter has the power to transform the way patients see." Join LENZ at Monterey Symposium, Oct 25th - 27th in Monterey, CA. www.EyeAmSelective.com #presbyopia #EyeAmSelective   

We are hiring! LENZ Therapeutics is searching for an AD/Director, Regulatory CMC. This position will support the development and successful performance of the CMC regulatory strategy for LENZ Therapeutics reporting to the VP, Regulatory and Clinical Operations. This role will create CMC regulatory strategy for original submissions and changes to approved processes. This candidate will also partner with cross-functional stakeholders to deliver input on regulatory submissions and manage regulatory dossiers throughout the product development lifecycle. If you are ready to join our team, click link below to apply: https://lnkd.in/gM8-_TFb

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia. FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 “With the acceptance of our New Drug Application for LNZ100, we are pleased to be one step closer towards potential approval and look forward to continuing to collaborate with the FDA to deliver the first once-daily, well-tolerated and rapid acting eye drop for the treatment of presbyopia to the 128 million individuals living with blurry near vision in the United States,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “Since our public debut in March 2024, we have generated tremendous momentum and demonstrated consistent clinical, regulatory and financial execution, and are focused on transforming LENZ into a robust commercial organization in anticipation of a potential launch as early as the second half of 2025.” Read full press release here: https://lnkd.in/ectNaV69

It has been a busy first day at the LENZ Therapeutics booth #3933, American Academy of Ophthalmology. Attendees are excited for the future of presbyopia solutions, interest is specifically focused on an option that could be iris-selective and able to achieve the ideal pupil size of below 2mm. #AcademyOfOphthalmology #PupilSizeMatters #Ophthalmology

LENZ Therapeutics welcomes S. Barry Eiden, OD, FAAO as Director, Medical Professional Relations. Dr. Eiden has been working with LENZ for several years as the founding member of our Optometric Advisory Board and as a consultant in the role of Senior Advisor for Professional Relations. Dr. Eiden is a highly respected clinician and founder of North Suburban Vision Consultants, a multi-specialty eye care practice in the Chicago suburbs. He is well known in the eye care field as a frequent lecturer, publisher in the professional literature and researcher. He has numerous adjunct faculty positions at schools of optometry and is past Chair of the American Optometric Association’s Cornea and Contact Lens section. Dr. Eiden’s extensive experience as a clinician, educator and researcher adds a wonderful skill set to our organization. Join us in welcoming Barry to the team!

LENZ Therapeutics welcomes Natasha K. Balani, OD, FAAO as Medical Science Liaison covering the Northwest territory. Natasha brings over 10 years of experience and clinical leadership as a practicing optometrist. She has previously held roles in clinical development at Alcon and as faculty at The Pacific University College of Optometry. Join us in welcoming Natasha to the team!

Ravi Patel, MD is inspired by the emerging solutions for presbyopia. Have you been following the latest research? "I currently advise LASIK candidates in their 40s that they'll need reading glasses for near vision. But a pupil-selective solution could give us a way to improve near vision without impacting distance vision. I'm excited by the research I've seen so far and look forward to introducing a new solution to my presbyopic patients who also desire LASIK". Visit LENZ at booth #3933 at American Academy of Ophthalmology, Oct 18th - 21st in Chicago, IL. www.EyeAmSelective.com #presbyopia #EyeAmSelective